About: Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.67 (+3.09%)
IKT NASDAQ Inhibikase Therapeutics Inc
Inhibikase Therapeutics Inc share price
Atividade de preço de IKT
Último preço
$ 1,670
Variação (24h)
0,05 USD (3,09%)
Volume
852.34K
Volume (média 4 sem.)
-
Abertura
$ 1,64
Variação do dia
$ 1,63 - $ 1,70
Fechamento anterior
$ 1,62
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
IKT price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals